Drug intelligence / Profile preview

mutant RAS peptide vaccine

Development stage: Unknown
Lead developer: Johns Hopkins University
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

The mutant RAS peptide vaccine is an immunotherapy composed of specific 13-mer mutant Ras peptides and a lipid-based adjuvant (DETOX™). It is designed to induce specific T-cell mediated immune responses against mutant Ras proteins, which are oncogenic drivers in various cancers, for the adjuvant treatment of pancreatic and colorectal cancers. The vaccine aims to leverage the immune system's ability to detect single amino-acid substitutions in mutant Ras, which are uniquely expressed in tumor tissue.

Other names: mutant ras vaccine

Targets

Divarasib-KRAS G12C-pMHC (Divarasib-modified KRAS G12C peptide–MHC class I complex)

Beyond the preview

Go deeper on mutant RAS peptide vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mutant RAS peptide vaccine.

Explore the full profile